The historical rank and industry rank for Lineage Cell Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:
LCTX'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 19.67 Med: 54 Max: 139.5
Current: 34.28
During the past years, Lineage Cell Therapeutics's highest Cyclically Adjusted PS Ratio was 139.50. The lowest was 19.67. And the median was 54.00.
LCTX's Cyclically Adjusted PS Ratio is ranked worse than 90.55% of 508
companies
in the Biotechnology industry
Industry Median: 5.385
vs LCTX: 34.28
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Lineage Cell Therapeutics's adjusted revenue per share data for the three months ended in Dec. 2023 was $0.012. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $0.03 for the trailing ten years ended in Dec. 2023.
Shiller PE for Stocks: The True Measure of Stock Valuation
Lineage Cell Therapeutics Cyclically Adjusted PS Ratio Historical Data
The historical data trend for Lineage Cell Therapeutics's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
* Premium members only.
Lineage Cell Therapeutics Cyclically Adjusted PS Ratio Chart
Competitive Comparison of Lineage Cell Therapeutics's Cyclically Adjusted PS Ratio
For the Biotechnology subindustry, Lineage Cell Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lineage Cell Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lineage Cell Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Lineage Cell Therapeutics's Cyclically Adjusted PS Ratio falls into.
Lineage Cell Therapeutics Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Lineage Cell Therapeutics (AMEX:LCTX) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Lineage Cell Therapeutics Cyclically Adjusted PS Ratio Related Terms
Thank you for viewing the detailed overview of Lineage Cell Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Lineage Cell Therapeutics (Lineage Cell Therapeutics) Business Description
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cell transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
LCTX has been successfully added to your 